A bispecific monoclonal antibody (BsMAb) recognising carcinoembryonic antigen (CEA) and doxorubicin (Dox) was used in colorimetric microcytotoxicity assays with 3 human colon cancer cell lines (COLO320DM, SKCO1 and LS174T) showing no, high or medium CEA expression, respectively. The IC50 values for
In vivo localization of a bispecific antibody which targets human t lymphocytes to lyse human colon cancer cells
β Scribed by Ian G. Barr; Sylvia Miescher; Vladimir Von Fliedner; Franz Buchegger; Catherine Barras; Antonio Lanzavecchia; Jean-Pierre Mach; Stefan Carrel
- Publisher
- John Wiley and Sons
- Year
- 1989
- Tongue
- French
- Weight
- 742 KB
- Volume
- 43
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
β¦ Synopsis
A bispecific MAb was derived from the fusion of a hybridoma producing MAb CD3 with a hybridoma producing MAb L-DI (which is directed against a 41-kDa glycoprotein expressed in most gastro-intestinal and pancreatic carcinomas). Bispecific antibody molecules were isolated from parental antibody molecules by the use of hydroxylapatite-HPLC and shown to target human cytolytic T lymphocytes, irrespective of their original specificity, to specifically lyse human colon carcinoma cells. Localization studies in vivo using nude mice bearing human colon carcinoma xenografts showed significant accumulation of the HPLC-purified '251-labelled bispecific antibodies into the tumor compared to '"I-labelled control CD3 antibody.
π SIMILAR VOLUMES
The following information was published incorrectly in the article by Avichezer et al. 1. On page 120, line 9, left-hand column: monoclonal anti-Tn antibody should read Ca 3783, not 3782, the latter has anti-T specificity. 2. On page 123, Table II, footnote 2 should read as follows: The data in bra